Developer docs
API playgroundTry for free, no card

Search company profiles

EnsoData

Full company profile

uuid00005kd

Namestring
EnsoData
Legal namestring
EnsoData, Inc.
Websiteurl
ensodata.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

EnsoData is a Madison, Wisconsin-based healthcare technology company founded in 2015 that develops FDA-cleared AI software for sleep medicine diagnostics and therapy monitoring. Its core platform is EnsoHub, a cloud-based unified environment that ingests and analyzes photoplethysmography (PPG) signals from FDA-cleared wearable pulse oximeters, alongside flow, snore, respiratory effort, SpO2, heart rate variability, actigraphy, position, and acoustic data channels. EnsoSleep provides AI-assisted scoring of polysomnography (PSG) and home sleep apnea tests (HSAT), achieving AASM Autoscoring Certification and delivering 62%+ time savings on PSGs and 68%+ on HSTs; EnsoHST enables multi-night home sleep testing of up to seven nights per patient with 92%+ sensitivity for sleep apnea detection; Therapy Track extends the platform into long-term monitoring and at-home titration across CPAP, HGNS, oral appliances, and GLP-1s; and the Celeste+ mobile app provides the patient-facing setup and data capture layer.

The company monetizes primarily through per-patient SaaS pricing for EnsoSleep AI scoring and EnsoHST multi-night testing, complemented by licensing/royalty arrangements such as its Takeda collaboration for narcolepsy type 1 AI algorithms and its acquisition of Resonea's acoustic diagnostic technology. It sells through an enterprise direct sales motion led by Chief Commercial Officer Bobby Cockrill and a parallel channel partner model with device manufacturers (BodiMetrics, Nonin, Viatom, Advanced Brain Monitoring, Happy Health) and healthcare providers (Aeroflow Sleep, Blackstone Medical Services, React Health). EnsoData serves 500+ sleep clinics and health systems, has supported care for 2.9 million patients, and processes 100,000+ patients monthly.

EnsoData is venture-backed, having raised $20M Series B led by Questa Capital in June 2025 and additional growth capital from CIBC Innovation Banking in May 2026, with earlier rounds led by Inspire Medical Systems and others. Strategic investors include Inspire Medical Systems and Takeda, and the company holds multiple certifications including four FDA 510(k) clearances, ISO 13485/MDSAP, HITRUST, and SOC 2 Type II. The business model is a vertically integrated AI sleep medicine platform spanning diagnostics, AI scoring, multi-night testing, and therapy monitoring, with regulatory and data assets serving as the primary competitive moats.

Short descriptiontext

EnsoData is a Madison, Wisconsin-based healthcare AI company that builds FDA-cleared software for sleep medicine, including AI sleep scoring, multi-night home sleep testing, and therapy monitoring. Its platform serves 500+ sleep clinics and has supported 2.9 million patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI sleep diagnostics, home sleep testing, polysomnography scoring software, sleep medicine AI platform, PPG waveform analysis
Industry4 codes
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming Services7371
Product category
AI Sleep Diagnostics Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1EnsoHST Per-Patient Pricing
TypeSubscription Recurring
Description

One flat price per patient for up to 7 nights of home sleep testing. No upfront device costs, no expensive disposables, no device return required for results. Includes AI analysis, cloud platform access, and report generation.

ensodata.com
2EnsoSleep AI Scoring
TypeSubscription Recurring
Description

Cloud-based AI scoring subscription for sleep labs. Integrates with existing PSG and HSAT devices and software. Pricing based on study volume with time savings enabling scalability.

ensodata.com
3Technology Acquisition (Resonea)
TypeOne Time License
Description

Acquired sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Expected US commercial availability within 2024.

openpr.com
4Takeda Collaboration
TypeLicensing Royalties
Description

Collaboration with Takeda to develop AI-based PSG algorithms for narcolepsy type 1 diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform.

ensodata.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1EnsoHST Multi-Night Testing - One flat fee per patient for up to 7 nights
ModelUnit PricingBilling cadencePay-as-you-go
Notes

One price per patient for up to 7 nights of multi-night home sleep testing. Includes AI analysis, cloud platform access, and comprehensive reporting. No device return required for results. Compatible with reusable pulse oximeters from manufacturers like Viatom, BodiMetrics, and Nonin.

ensodata.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1EnsoHST
Description

FDA-cleared, multi-night home sleep testing solution that leverages PPG signals from wearable pulse oximeters to deliver fast, reliable, and comprehensive sleep disorder diagnostics. Enables testing for up to 7 nights per patient with AI-powered analysis.

ensodata.com
+4 more records
Core offering1 text field

EnsoData develops and sells FDA-cleared AI/ML-powered software for sleep medicine diagnostics and therapy monitoring. Its core offerings include EnsoHST (multi-night home sleep testing), EnsoSleep (AI-assisted PSG and HSAT scoring), EnsoHub (unified cloud-based study management platform), and Therapy Track (long-term therapy monitoring). The platform analyzes physiological signals from third-party pulse oximeters to deliver automated sleep apnea detection, scoring, and reporting for sleep clinics and health systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 11 values shown
  • 92%+ sensitivity for Sleep Apnea detection
+10 more records
Product overview1 text field

EnsoData offers a unified AI-powered ecosystem for sleep medicine diagnostics and therapy management. The core platform consists of EnsoHST (multi-night FDA-cleared home sleep testing), EnsoSleep (AI-assisted scoring for PSGs and HSATs), and EnsoHub (cloud-based unified study management platform). These products work together to power the complete sleep care journey from diagnosis through long-term therapy monitoring. EnsoHST leverages photoplethysmography signals from wearable pulse oximeters to enable affordable, patient-friendly multi-night testing while EnsoSleep provides automated scoring analysis. Therapy Track extends the ecosystem to long-term therapy monitoring. The system integrates with third-party pulse oximetry devices (BodiMetrics, Nonin, Viatom), ePrescribing platforms (Parachute Health), and therapy devices (React Health) to create a comprehensive connected care solution.

Product and service5 records
1EnsoHST
CategoryAI Sleep Diagnostics Software
Description

FDA-cleared multi-night home sleep testing (HSAT) solution that analyzes photoplethysmography (PPG) signals from wearable pulse oximeters to automatically score sleep apnea events. Supports up to 7 nights of testing per patient with AI-driven analysis available within minutes of study completion. Clinically validated with 92%+ sensitivity for sleep apnea and 97% patient success rate.

2EnsoSleep
CategoryAI Sleep Diagnostics Software
Description

FDA-cleared AI-assisted sleep scoring and analysis solution for polysomnographies (PSGs) and home sleep apnea tests (HSATs). Automates detection of sleep-disordered breathing, sleep staging, and generates diagnostic reports. Achieves 93% diagnostic AHI agreement and 86% sleep staging agreement with gold-standard manual scoring, with AASM Autoscoring Certification achieved in April 2024.

3EnsoHub
CategoryCloud-based Sleep Study Management Platform
Description

Cloud-based unified platform for accessing, reviewing, editing, and reporting on all AI-scored HSAT, PSG, and PPG-based sleep studies across all locations, devices, and sleep techs. Centralizes study management with professional, clinic-branded reports that auto-update with physician edits, eliminating the need for VPNs.

4Therapy Track
CategorySleep Therapy Monitoring Software
Description

Long-term therapy monitoring and titration solution that extends the sleep care pathway from diagnostic testing through ongoing treatment. Monitors CPAP, HGNS, oral appliances, GLP-1s, and emerging therapies using the same devices used for diagnostic testing, enabling at-home therapy titration without repeat in-lab studies.

5Celeste+ Mobile App
CategoryPatient-facing Mobile App
Description

Patient-facing FDA-cleared mobile application for EnsoHST multi-night home sleep testing. Guides patient setup with connected pulse oximetry devices, automatically uploads data upon study completion, and provides immediate confirmation or guidance to test additional nights. Includes Acoustic Flow, Snore, and Actigraphy channels.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Collaboration to develop and validate AI-based PSG algorithms for narcolepsy type 1 (NT1) diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform for clinical availability.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-10
Description

Acquisition of sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Includes FDA-cleared mobile app technology for pre-screening and diagnosis.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Partnership in October 2023 to improve patient adherence to sleep apnea therapy through AI-powered monitoring and predictive analytics.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Aeroflow Sleep partnership to deploy EnsoData's predictive AI for proactive sleep apnea management across the United States.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to simplify at-home diagnosis and treatment monitoring of patients with sleep apnea, reducing barriers to care by putting patients in control of their health journey.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to address the 80% of undiagnosed sleep apnea cases through Blackstone's medical services and EnsoData's diagnostic technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in sleep apnea and respiratory care devices (CPAP, masks) with growing digital health software (myAir, AirView) for therapy monitoring. Comparable to EnsoData as both target the sleep apnea care continuum, though ResMed operates upstream in therapy hardware rather than diagnostics AI.

TypeDirect peer
Description

ZOLL Itamar Medical makes WatchPAT, a proprietary home sleep apnea testing device with embedded AI-driven autoscoring. Direct competitor to EnsoHST in the HSAT market, with similar FDA-cleared automated scoring positioning.

TypeDirect peer
Description

Iceland-based manufacturer of PSG and HSAT hardware (Noxturnal software) with AI-assisted scoring capabilities. Competes with EnsoData in the sleep diagnostics market, particularly for in-lab PSG and home sleep testing workflows.

TypeDirect peer
Description

U.S. medical device company offering home sleep testing devices (SleepView) and cloud-based sleep scoring services. Direct competitor in the HSAT and AI-assisted scoring space, with comparable clinic-targeted sales motion.

TypeOthers
Description

Medical device company behind Inspire UAS therapy for sleep apnea (investor and board seat in EnsoData via CTO John Rondoni). Adjacent in the sleep apnea care continuum, providing HGNS therapy data that integrates with EnsoData's diagnostic and monitoring platform.

TypeOthers
Description

Respiratory and sleep therapy device company (CPAP, masks) partnered with EnsoData since October 2023 to improve therapy adherence via AI monitoring. Comparable in targeting the same sleep apnea patient population but with therapy hardware rather than diagnostic AI.

TypeBroad incumbent
Description

Chinese sleep and respiratory device manufacturer with global HSAT and CPAP footprint. Competes in the same clinical channel (sleep labs) with hardware-centric approach, contrasting with EnsoData's hardware-agnostic AI platform model.

TypeDirect peer
Description

Australia-based sleep diagnostics company offering PSG and HSAT hardware with Profusion software. Competes in EnsoData's FDA-cleared Australia/Canada markets with integrated hardware + scoring solutions.

TypeEmerging player
Description

Canadian sleep diagnostics AI company offering automated PSG scoring software with comparable clinical validation and time-savings positioning. Direct emerging competitor in the AI sleep scoring category.

TypeEmerging player
Description

Digital health company applying AI and multimodal data to sleep and pain management. Comparable in applying AI to sleep medicine use cases but with adjacent therapeutic focus rather than diagnostic scoring.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EnsoData

AI Sleep Diagnostics Softwareensodata.com

EnsoData is a Madison, Wisconsin-based healthcare AI company that builds FDA-cleared software for sleep medicine, including AI sleep scoring, multi-night home sleep testing, and therapy monitoring. Its platform serves 500+ sleep clinics and has supported 2.9 million patients.

What EnsoData does

EnsoData is a Madison, Wisconsin-based healthcare technology company founded in 2015 that develops FDA-cleared AI software for sleep medicine diagnostics and therapy monitoring. Its core platform is EnsoHub, a cloud-based unified environment that ingests and analyzes photoplethysmography (PPG) signals from FDA-cleared wearable pulse oximeters, alongside flow, snore, respiratory effort, SpO2, heart rate variability, actigraphy, position, and acoustic data channels. EnsoSleep provides AI-assisted scoring of polysomnography (PSG) and home sleep apnea tests (HSAT), achieving AASM Autoscoring Certification and delivering 62%+ time savings on PSGs and 68%+ on HSTs; EnsoHST enables multi-night home sleep testing of up to seven nights per patient with 92%+ sensitivity for sleep apnea detection; Therapy Track extends the platform into long-term monitoring and at-home titration across CPAP, HGNS, oral appliances, and GLP-1s; and the Celeste+ mobile app provides the patient-facing setup and data capture layer.

The company monetizes primarily through per-patient SaaS pricing for EnsoSleep AI scoring and EnsoHST multi-night testing, complemented by licensing/royalty arrangements such as its Takeda collaboration for narcolepsy type 1 AI algorithms and its acquisition of Resonea's acoustic diagnostic technology. It sells through an enterprise direct sales motion led by Chief Commercial Officer Bobby Cockrill and a parallel channel partner model with device manufacturers (BodiMetrics, Nonin, Viatom, Advanced Brain Monitoring, Happy Health) and healthcare providers (Aeroflow Sleep, Blackstone Medical Services, React Health). EnsoData serves 500+ sleep clinics and health systems, has supported care for 2.9 million patients, and processes 100,000+ patients monthly.

EnsoData is venture-backed, having raised $20M Series B led by Questa Capital in June 2025 and additional growth capital from CIBC Innovation Banking in May 2026, with earlier rounds led by Inspire Medical Systems and others. Strategic investors include Inspire Medical Systems and Takeda, and the company holds multiple certifications including four FDA 510(k) clearances, ISO 13485/MDSAP, HITRUST, and SOC 2 Type II. The business model is a vertically integrated AI sleep medicine platform spanning diagnostics, AI scoring, multi-night testing, and therapy monitoring, with regulatory and data assets serving as the primary competitive moats.

EnsoData firmographics

Firmographics
Name
EnsoData
Legal name
EnsoData, Inc.
Website
https://ensodata.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
EnsoData is a Madison, Wisconsin-based healthcare AI company that builds FDA-cleared software for sleep medicine, including AI sleep scoring, multi-night home sleep testing, and therapy monitoring. Its platform serves 500+ sleep clinics and has supported 2.9 million patients.
Ownership category
akta.pro rank

EnsoData industry classification

Industry
Product category
AI Sleep Diagnostics Software
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • AI sleep diagnostics
  • Home sleep testing
  • Polysomnography scoring software
  • Sleep medicine AI platform
  • PPG waveform analysis

Where EnsoData is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EnsoData business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. EnsoHST Per-Patient Pricing: One flat price per patient for up to 7 nights of home sleep testing. No upfront device costs, no expensive disposables, no device return required for results. Includes AI analysis, cloud platform access, and report generation.
  2. EnsoSleep AI Scoring: Cloud-based AI scoring subscription for sleep labs. Integrates with existing PSG and HSAT devices and software. Pricing based on study volume with time savings enabling scalability.
  3. Technology Acquisition (Resonea): Acquired sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Expected US commercial availability within 2024.
  4. Takeda Collaboration: Collaboration with Takeda to develop AI-based PSG algorithms for narcolepsy type 1 diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goEnsoHST Multi-Night Testing - One flat fee per patient for up to 7 nights

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

EnsoData product offering

Product offering

Core offering

EnsoData develops and sells FDA-cleared AI/ML-powered software for sleep medicine diagnostics and therapy monitoring. Its core offerings include EnsoHST (multi-night home sleep testing), EnsoSleep (AI-assisted PSG and HSAT scoring), EnsoHub (unified cloud-based study management platform), and Therapy Track (long-term therapy monitoring). The platform analyzes physiological signals from third-party pulse oximeters to deliver automated sleep apnea detection, scoring, and reporting for sleep clinics and health systems.

Product overview

EnsoData offers a unified AI-powered ecosystem for sleep medicine diagnostics and therapy management. The core platform consists of EnsoHST (multi-night FDA-cleared home sleep testing), EnsoSleep (AI-assisted scoring for PSGs and HSATs), and EnsoHub (cloud-based unified study management platform). These products work together to power the complete sleep care journey from diagnosis through long-term therapy monitoring. EnsoHST leverages photoplethysmography signals from wearable pulse oximeters to enable affordable, patient-friendly multi-night testing while EnsoSleep provides automated scoring analysis. Therapy Track extends the ecosystem to long-term therapy monitoring. The system integrates with third-party pulse oximetry devices (BodiMetrics, Nonin, Viatom), ePrescribing platforms (Parachute Health), and therapy devices (React Health) to create a comprehensive connected care solution.

Differentiator

Problem solved

Functional benefit

Brands

  • EnsoHST: FDA-cleared, multi-night home sleep testing solution that leverages PPG signals from wearable pulse oximeters to deliver fast, reliable, and comprehensive sleep disorder diagnostics. Enables testing for up to 7 nights per patient with AI-powered analysis.
  • EnsoSleep
  • EnsoHub
  • Therapy Track
  • Celeste+ (Mobile App)

Products and services

  • EnsoHST FDA-cleared multi-night home sleep testing (HSAT) solution that analyzes photoplethysmography (PPG) signals from wearable pulse oximeters to automatically score sleep apnea events. Supports up to 7 nights of testing per patient with AI-driven analysis available within minutes of study completion. Clinically validated with 92%+ sensitivity for sleep apnea and 97% patient success rate.
  • EnsoSleep FDA-cleared AI-assisted sleep scoring and analysis solution for polysomnographies (PSGs) and home sleep apnea tests (HSATs). Automates detection of sleep-disordered breathing, sleep staging, and generates diagnostic reports. Achieves 93% diagnostic AHI agreement and 86% sleep staging agreement with gold-standard manual scoring, with AASM Autoscoring Certification achieved in April 2024.
  • EnsoHub Cloud-based unified platform for accessing, reviewing, editing, and reporting on all AI-scored HSAT, PSG, and PPG-based sleep studies across all locations, devices, and sleep techs. Centralizes study management with professional, clinic-branded reports that auto-update with physician edits, eliminating the need for VPNs.
  • Therapy Track Long-term therapy monitoring and titration solution that extends the sleep care pathway from diagnostic testing through ongoing treatment. Monitors CPAP, HGNS, oral appliances, GLP-1s, and emerging therapies using the same devices used for diagnostic testing, enabling at-home therapy titration without repeat in-lab studies.
  • Celeste+ Mobile App Patient-facing FDA-cleared mobile application for EnsoHST multi-night home sleep testing. Guides patient setup with connected pulse oximetry devices, automatically uploads data upon study completion, and provides immediate confirmation or guidance to test additional nights. Includes Acoustic Flow, Snore, and Actigraphy channels.

Quantifiable outcome

  • 92%+ sensitivity for Sleep Apnea detection
  • +10 more outcomes

Companies that use EnsoData

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

EnsoData technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability9 records

Feature8 records

EnsoData partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, core and minor.

  • Takeda PharmaceuticalsstrategicStrategic or Co-development Partner · 21 August 2025Collaboration to develop and validate AI-based PSG algorithms for narcolepsy type 1 (NT1) diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform for clinical availability.
  • ResoneacoreTechnology or Integration · 10 July 2024Acquisition of sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Includes FDA-cleared mobile app technology for pre-screening and diagnosis.
  • React HealthstrategicStrategic or Co-development Partner · 1 October 2023Partnership in October 2023 to improve patient adherence to sleep apnea therapy through AI-powered monitoring and predictive analytics.
  • Aeroflow SleepstrategicStrategic or Co-development PartnerAeroflow Sleep partnership to deploy EnsoData's predictive AI for proactive sleep apnea management across the United States.
  • Happy HealthminorChannel Partner/ Reseller/ DistributorPartnership to simplify at-home diagnosis and treatment monitoring of patients with sleep apnea, reducing barriers to care by putting patients in control of their health journey.
  • Blackstone Medical ServicesminorChannel Partner/ Reseller/ DistributorPartnership to address the 80% of undiagnosed sleep apnea cases through Blackstone's medical services and EnsoData's diagnostic technology.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

EnsoData competitors and assessment

Company assessment

Broad incumbents

  • ResMed: Global leader in sleep apnea and respiratory care devices (CPAP, masks) with growing digital health software (myAir, AirView) for therapy monitoring. Comparable to EnsoData as both target the sleep apnea care continuum, though ResMed operates upstream in therapy hardware rather than diagnostics AI.
  • BMC Medical: Chinese sleep and respiratory device manufacturer with global HSAT and CPAP footprint. Competes in the same clinical channel (sleep labs) with hardware-centric approach, contrasting with EnsoData's hardware-agnostic AI platform model.

Direct peers

  • Itamar Medical (WatchPAT): ZOLL Itamar Medical makes WatchPAT, a proprietary home sleep apnea testing device with embedded AI-driven autoscoring. Direct competitor to EnsoHST in the HSAT market, with similar FDA-cleared automated scoring positioning.
  • Nox Medical: Iceland-based manufacturer of PSG and HSAT hardware (Noxturnal software) with AI-assisted scoring capabilities. Competes with EnsoData in the sleep diagnostics market, particularly for in-lab PSG and home sleep testing workflows.
  • CleveMed: U.S. medical device company offering home sleep testing devices (SleepView) and cloud-based sleep scoring services. Direct competitor in the HSAT and AI-assisted scoring space, with comparable clinic-targeted sales motion.
  • Compumedics: Australia-based sleep diagnostics company offering PSG and HSAT hardware with Profusion software. Competes in EnsoData's FDA-cleared Australia/Canada markets with integrated hardware + scoring solutions.

Others

  • Inspire Medical Systems: Medical device company behind Inspire UAS therapy for sleep apnea (investor and board seat in EnsoData via CTO John Rondoni). Adjacent in the sleep apnea care continuum, providing HGNS therapy data that integrates with EnsoData's diagnostic and monitoring platform.
  • React Health: Respiratory and sleep therapy device company (CPAP, masks) partnered with EnsoData since October 2023 to improve therapy adherence via AI monitoring. Comparable in targeting the same sleep apnea patient population but with therapy hardware rather than diagnostic AI.

Emerging players

  • Cerebra Health: Canadian sleep diagnostics AI company offering automated PSG scoring software with comparable clinical validation and time-savings positioning. Direct emerging competitor in the AI sleep scoring category.
  • Sana Health: Digital health company applying AI and multimodal data to sleep and pain management. Comparable in applying AI to sleep medicine use cases but with adjacent therapeutic focus rather than diagnostic scoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

EnsoData social profiles

Digital presence

EnsoData compliance and trust

Trust signal

Compliance6 records

EnsoData financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EnsoData leadership team

Management profile

Number of profiles

Profiles20 records

EnsoData funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EnsoData M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnsoData

What does EnsoData do?

EnsoData develops and sells FDA-cleared AI/ML-powered software for sleep medicine diagnostics and therapy monitoring. Its core offerings include EnsoHST (multi-night home sleep testing), EnsoSleep (AI-assisted PSG and HSAT scoring), EnsoHub (unified cloud-based study management platform), and Therapy Track (long-term therapy monitoring). The platform analyzes physiological signals from third-party pulse oximeters to deliver automated sleep apnea detection, scoring, and reporting for sleep clinics and health systems.

Is EnsoData a public or private company?

EnsoData is a private company. It is classified as venture growth investor backed and is currently operating.

When was EnsoData founded?

EnsoData was founded in 2015. It employs 51 to 100 people.

Where is EnsoData based?

EnsoData is headquartered in Madison, United States, in the North America region.

How does EnsoData make money?

Four revenue lines are on record. EnsoHST Per-Patient Pricing is the primary driver. The others are ensoSleep AI Scoring, technology Acquisition (Resonea) and takeda Collaboration.

Who are EnsoData's main competitors?

Broad incumbents on record are ResMed and BMC Medical. Direct peers are Itamar Medical (WatchPAT), Nox Medical, CleveMed and Compumedics. Others are Inspire Medical Systems and React Health. Emerging players are Cerebra Health and Sana Health.

Does EnsoData have an API?

No public API is recorded for EnsoData.

What industry is EnsoData in?

EnsoData's product category is AI Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 5182 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0EnsoData Secures Growth Capital From CIBC Innovation BankingCIBC Innovation Banking has provided growth capital financing to EnsoData, a healthcare technology company based in Madison, Wisconsin that develops AI-powered sleep medicine solutions. The financing will support EnsoData's continued expansion and accelerate investment in its FDA-cleared AI-driven diagnostics technology. EnsoData's flagship product EnsoHST is a multi-night home sleep testing solution that has supported care for more than 2.9 million patients to date.FinSMEsEnsoData Receives Investment From CIBC Innovation BankingEnsoData, a Madison, WI-based AI sleep medicine provider, received undisclosed financing from CIBC Innovation Banking. The company will use the funds to expand operations and R&D, and its FDA-cleared EnsoHST product has supported over 2.9 million patients.Business Wire BlogCIBC Innovation Banking Provides Growth Capital to EnsoDataCIBC Innovation Banking announced it has provided growth capital financing for EnsoData, a healthcare technology company specializing in AI-powered software solutions for sleep medicine. EnsoData's flagship product EnsoHST is an FDA-cleared multi-night home sleep testing solution that uses a wearable device and mobile app to deliver clinically reliable diagnostic results. The funding will support EnsoData's expansion of access to sleep care and accelerate investment in AI-driven diagnostic innovations across additional clinical domains.VentureBeatCIBC Innovation Banking Provides Growth Capital to EnsoDataCIBC Innovation Banking provided growth capital financing to EnsoData, an AI-powered sleep medicine software provider. EnsoData's flagship product, EnsoHST, is a multi-night home sleep testing solution that has supported over 2.9 million patients. The funding will enable expansion of access to sleep care and investment in AI-driven innovations.EnsodataThe Big News Trifecta: $20m Series A Extension, New President, Back-to-Back Best WorkplacesEnsoData closed a $20 million Series A extension led by Inspire Medical Systems, appointing Justin Mortara as president. The company's AI sleep diagnosis tool has supported over 500,000 patients and won Inc. Magazine's Best Workplaces award for the second year. The funding will scale multinational expansion and commercial partnerships.Sleep ReviewClinical Validation of EnsoData’s Hardware-Free Flow ChannelEnsoData released a white paper detailing the clinical validation of its hardware-free flow channel, which utilizes smartphone-recorded breathing sounds to generate respiratory flow data for home sleep studies. The study compared this method against traditional polysomnography (PSG) nasal pressure across 62 cases, finding strong agreement with a mean AHI difference of only 0.88 events per hour and 92% accuracy at key severity thresholds.GlobeNewswireAI-Enhanced Chronic Obstructive Sleep Apnea Coaches | A $1.92 Billion Global Market in 2026The AI-enhanced chronic obstructive sleep apnea (OSA) coach market is projected to grow from $1.61 billion in 2025 to $1.92 billion in 2026, advancing at a 19.5% compound annual growth rate, with further expansion expected to reach $3.88 billion by 2030. Key growth drivers include rising sleep disorder incidence, increased adoption of AI tools for chronic disease management, expanded remote patient monitoring, and growing integration with connected medical devices. Notable industry developments include ResMed Inc.'s launch of the AirCurve 11 bilevel device and Aeroflow Sleep's partnership with EnsoData to deploy predictive AI for proactive sleep apnea management in the United States.openPR.comTop Companies and Industry Competition in the Sleeping Aids MarketThe sleeping aids market is projected to reach $137.07 billion by 2030 with a 7.6% CAGR, driven by aging populations, wearable technology adoption, and rising sleep disorder diagnoses. In October 2025, Ireland-based biopharmaceutical company Alkermes Plc acquired Avadel Pharmaceuticals for $2.1 billion to expand its sleep medicine portfolio, while US-based EnsoData partnered with React Health in October 2023 to improve patient adherence to sleep apnea therapy.openPR.comKey Players and Market Competition in the Sleep Apnea Devices IndustryThe sleep apnea devices market is projected to reach $12.54 billion by 2030, growing at a compound annual growth rate of 8.5%, driven by rising home healthcare services, an aging population, and advancements in sleep monitoring technology. In July 2024, EnsoData, a US-based software company, acquired sleep testing diagnostic technology from Resonea to enhance its sleep apnea screening and diagnosis capabilities. Additionally, in May 2023, US-based Signifier Medical Technologies LLC partnered with Hong Kong-based Sunrise Healthcare Technology to integrate AI-driven solutions with Signifier's daytime sleep apnea therapy device eXciteOSA.